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Poster presentation
Some autistic children also have symptoms of depres-
sion, anxiety or obsessive-compulsive disorder (OCD).
Aromatic anti-epileptic drugs (AEDs) may be used as a
mood-stabilizing medication to treat these symptoms,
including carbamazepine (CBZ), oxcarbazepine (OX-
CBZ), and lamotrigene (LMG). Moreover, one in every
four autistic spectrum disorder children have seizures,
the use of AED becomes imperative in managing symp-
toms. Previous studies found a strong association
between HLA-B*1502 and carbamazepine (CBZ)-induced
cutaneous adverse reactions in Thai epileptic patients.
This study aimed to identify whether HLA-B*1502 is
associated with AEDs-induced hypersensitivity syndrome
(HSS) reactions and also determine the frequency of
HLA-B*15:02 in autistic spectrum disorder (ASD) in
Thailand. In this study, patients that developed fever and
cutaneous eruptions in the presence or absence of organ
involvement with exposure to carbamazepine (CBZ),
phenytoin (PHY), or lamotrigine (LTG) were enrolled.
HLA-B* 15:02 was then determined in 21 patients with
AED-induced HSS (6 with CBZ-HSS, 4 PHY-HSS
patients and 11 LTG-HSS patients and 292 children with
ASD. HLA-B genotyping using PCR-SSOP methods was
performed. HLA-B*15:02 was observed with HSS-induced
by AEDs, which included carbamazepine (n=4; 66.7%),
phenytoin (n=2; 50%), and lamotrigine (n=3; 27%). In
addition, the allele frequencies of HLA-B*15:02 in ASD
was 14.72% (43/292). HSS-induced by CBZ, PHY and
LMG is strongly, moderately and slightly associated with
HLA-B*15:02 in Thai patients, respectively. Our findings
suggest that HLA-B*15:02 testing before AED therapy
would be effective at risk of hypersensitivity and applic-
able to ASD populations providing hope for prevention
in the future.
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